Physician profile
Miranda Shelly
NPI 1679270706
$5,384.20
in general payments reported to CMS, 2019-2025
26 companies · $1,760 in 2025
The $1,760 reported for 2025 was more than what 91% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $992 · 2024: $2,632 · 2025: $1,760.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,353 · Education: $31.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,352.70 |
| Education | $31.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,533.82 | 2023-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $700.36 | 2023-2025 | Xifaxan, Trulance, Relistor |
| Takeda Pharmaceuticals U.S.A., INC. | $680.40 | 2023-2025 | Entyvio, Gattex |
| Janssen Biotech, INC. | $403.87 | 2024-2025 | Tremfya, Stelara |
| Phathom Pharmaceuticals, INC. | $295.37 | 2024-2025 | Voquezna |
| Qol Medical, LLC | $275.00 | 2023-2025 | Sucraid, Sucraid |
| Ardelyx, INC. | $249.26 | 2023-2025 | Ibsrela |
| Genzyme Corporation | $242.37 | 2023-2025 | |
| Pfizer INC. | $176.09 | 2024-2025 | |
| Ipsen Biopharmaceuticals, INC | $136.32 | 2024-2025 | Iqirvo, Bylvay |
| Organon LLC | $106.93 | 2024-2025 | Nexplanon, Hadlima, Renflexis |
| Vivus LLC | $106.69 | 2023-2025 | Qsymia, Pancreaze |
| Intercept Pharmaceuticals, INC. | $91.68 | 2023 | Ocaliva |
| Celltrion USA INC. | $88.17 | 2024-2025 | Vegzelma, Zymfentra |
| Ferring Pharmaceuticals INC. | $48.59 | 2023 | Rebyota |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius Kabi USA, LLC | $33.18 | 2024 | Idacio |
| Mylan Institutional INC. | $30.48 | 2023 | Hulio |
| Amgen INC. | $29.64 | 2023 | Avsola, Amjevita |
| Gilead Sciences, INC. | $24.92 | 2024 | |
| Aimmune Therapeutics, INC. | $24.10 | 2025 | Zenpep |
| Madrigal Pharmaceuticals | $22.26 | 2024 | Resmetirom |
| Novo Nordisk INC | $21.30 | 2025 | Wegovy |
| Blueprint Medicines Corporation | $20.59 | 2025 | Ayvakit |
| W. L. Gore & Associates, INC. | $14.55 | 2023 | Gore Cardioform Septal Occluder |
| Celgene Corporation | $14.23 | 2024 | Zeposia |
| Cumberland Pharmaceuticals, INC. | $14.03 | 2024 | Sancuso |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Miranda Shelly listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.